Top-Rated Stocks NASDAQ:RCKT Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $20.24 -0.76 (-3.62%) (As of 02/8/2023 12:39 PM ET) Add Compare Share Share Today's Range$19.96▼$20.8450-Day Range$17.62▼$22.7652-Week Range$7.57▼$23.48Volume178,225 shsAverage Volume764,374 shsMarket Capitalization$1.53 billionP/E RatioN/ADividend YieldN/APrice Target$52.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.9% Upside$52.75 Price TargetShort InterestBearish9.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.48Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.03) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector345th out of 1,029 stocksPharmaceutical Preparations Industry166th out of 504 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.75, Rocket Pharmaceuticals has a forecasted upside of 161.9% from its current price of $20.14.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.79% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 2.5 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 12 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows15 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 114% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders33.67% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.23% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($3.03) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rocket Pharmaceuticals (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.Read More Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Stock News HeadlinesJanuary 12, 2023 | marketbeat.com 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 (RCKT)Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.February 8, 2023 | marketwatch.comMultiple Rocket Launchers Market Size 2023 with Regional Scope, Report Coverage, Historic Data and Outlook 2028February 8, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.February 7, 2023 | usnews.comU.S. Approves Sale up to $10 Billion Sale of HIMARS Rocket Launchers and Ammunition to Poland PentagonFebruary 7, 2023 | marketwatch.comProbe Rocket Market Research Reports, Industry Size, Growth Opportunity, Regional Analysis 2023-2028February 7, 2023 | marketwatch.comRocket Pharma Gets RMAT Designation for RP-A501 Treatment for Danon DiseaseFebruary 7, 2023 | finance.yahoo.comRocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon DiseaseFebruary 6, 2023 | msn.comSenate League championship takes center stage Wednesday at Rocket Mortgage Fieldhouse: What to watch in boys basketballFebruary 8, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.February 6, 2023 | marketwatch.comMan-Portable Rocket Launcher Market [New Report] by Size, Leading Competitors, Market Strategies, and Trend Forecast to 2028February 5, 2023 | finance.yahoo.comEven with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70kFebruary 3, 2023 | americanbankingnews.comMorgan Stanley Initiates Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT)February 3, 2023 | americanbankingnews.comBrokerages Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Target Price at $53.45January 28, 2023 | finance.yahoo.com12 Cash-Rich Small Cap Stocks To Invest InJanuary 25, 2023 | msn.comRewatch Space Startup Rocket Lab's First Launch From the USJanuary 25, 2023 | msn.comRocket Lab aces its first launch from U.S. soilJanuary 24, 2023 | msn.comRocket Lab launches 1st Electron booster from US soil in twilight liftoffJanuary 24, 2023 | msn.comRocket Lab launches 3 satellites in first mission from U.S. soilJanuary 24, 2023 | msn.comWatch live as Rocket Lab launches its first rocket from the USJanuary 24, 2023 | techcrunch.comWatch Rocket Lab launch Electron from US soil for the first timeJanuary 24, 2023 | msn.comRocket Lab's First Launch From the US Could Be Visible to Millions TonightJanuary 24, 2023 | msn.comPompeo says Trump had to explain 'Rocket Man' joke to Kim Jong Un: BookJanuary 24, 2023 | msn.comWatch live: Rocket Lab's big Electron launch from Wallops set for tonightJanuary 24, 2023 | msn.comWatch Rocket Lab launch Electron from U.S. soil for the first timeJanuary 23, 2023 | msn.comTrump had to explain his 'Little Rocket Man' nickname to Kim Jong Un, Mike Pompeo says in new bookJanuary 23, 2023 | msn.comRocket Lab now targeting Jan. 24 for 1st-ever launch from US. Here's how to watch live.January 23, 2023 | msn.comThe Latest Analyst Ratings for Rocket PharmaceuticalsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Company Calendar Last Earnings11/03/2021Today2/08/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees151Year Founded2018Price Target and Rating Average Stock Price Forecast$52.75 High Stock Price Forecast$75.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+160.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.01% Return on Assets-44.15% Debt Debt-to-Equity Ratio0.05 Current Ratio10.31 Quick Ratio10.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.05 per share Price / Book2.87Miscellaneous Outstanding Shares75,680,000Free Float50,201,000Market Cap$1.53 billion OptionableOptionable Beta1.23 Social Links Key ExecutivesGaurav D. ShahChief Executive Officer & DirectorKinnari PatelPresident & Chief Operating OfficerJohn C. MilitelloTreasurer, Chief Financial & Accounting OfficerJonathan David SchwartzChief Medical Officer & SVP-Clinical DevelopmentMayo PujolsChief Technical Officer & Executive Vice PresidentKey CompetitorsPliant TherapeuticsNASDAQ:PLRXNuvalentNASDAQ:NUVLAgios PharmaceuticalsNASDAQ:AGIOReata PharmaceuticalsNASDAQ:RETAArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsGranite Point Capital Management L.P.Bought 20,000 shares on 2/7/2023Ownership: 0.185%TD Asset Management IncBought 9,063 shares on 2/7/2023Ownership: 0.056%State Board of Administration of Florida Retirement SystemSold 1,410 shares on 2/7/2023Ownership: 0.022%Mitsubishi UFJ Kokusai Asset Management Co. Ltd.Sold 9,786 shares on 2/7/2023Ownership: 0.020%Envestnet Asset Management Inc.Bought 13,040 shares on 2/7/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions RCKT Stock - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price forecast for 2023? 12 analysts have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's stock price to reach $52.75 in the next year. This suggests a possible upside of 151.2% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2023? Rocket Pharmaceuticals' stock was trading at $19.57 on January 1st, 2023. Since then, RCKT shares have increased by 7.3% and is now trading at $21.00. View the best growth stocks for 2023 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.19. During the same period in the prior year, the business posted ($0.53) EPS. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.33%), Comerica Bank (0.38%), WCM Investment Management LLC (0.33%), Nisa Investment Advisors LLC (0.19%), Granite Point Capital Management L.P. (0.18%) and Synovus Financial Corp (0.17%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $21.00. How much money does Rocket Pharmaceuticals make? Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.59 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis. How many employees does Rocket Pharmaceuticals have? The company employs 151 workers across the globe. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585. This page (NASDAQ:RCKT) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.